Dapagliflozin for fatty liver disease in people with prediabetes or type 2 diabetes
Tests dapagliflozin on fatty liver disease in adults with prediabetes or type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07891234, who can take part
Where in Egypt
- Ain Shams University HospitalCairo, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sherihan AboElyazed Mohamed Khalil
- Trial code
- NCT07891234
- Record updated
- 23 October 2026
- Original description
Metabolic-dysfunction-associated fatty liver disease (MAFLD) has evolved as a major health problem recently. Discovering ways to prevent or delay the progression of MAFLD has become a global focus. Lifestyle modifications remain the cornerstone of MAFLD treatment, even though various pharmaceutical interventions are currently under clinical trial. Among them, sodium-glucose co-transporter type-2 inhibitors (SGLT-2i) are emerging as promising agents.Read full original descriptionShow less
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction Associated Fatty Liver Disease in Patients With Insulin Resistance
Metabolic-dysfunction-associated fatty liver disease (MAFLD) has evolved as a major health problem recently. Discovering ways to prevent or delay the progression of MAFLD has become a global focus. Lifestyle modifications remain the cornerstone of MAFLD treatment, even though various pharmaceutical interventions are currently under clinical trial. Among them, sodium-glucose co-transporter type-2 inhibitors (SGLT-2i) are emerging as promising agents.
In this study we aim to evaluate the effect of SGLT2 inhibitors on fatty liver disease in patients with prediabetes and type 2 diabetes
Inclusion: Patients of both sexes aged≥ 18 years; Obese and non-obese patients; Patients with prediabetes or type 2 diabetes.
Exclusion: Patients with liver disease other than NAFLD; Patients with type 1 diabetes; Patients with malignancy; pregnant patients.